RecruitingNCT05270499

Aveir VR Real-World Evidence Post-Approval Study

Aveir Single-Chamber Leadless Pacemaker Real-World Evidence Post-Approval Study

Sponsor

Abbott Medical Devices

Enrollment

2,100 participants

Start Date

Jun 21, 2022

Study Type

OBSERVATIONAL

Conditions

Arrythmia Bradycardia Cardiac Pacemaker

Summary

The purpose of this post-approval study is to evaluate the long-term safety of the single-chamber Aveir VR leadless pacemaker using real-world evidence methods.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Eligibility Criteria:
Implanted with an Aveir VR leadless pacemaker
Continuous enrollment in Medicare Part A and Part B for 12 months prior to implant and for 30 days after implant, except in the case of death within the 30-day period
Ability to link with Medicare fee-for-service data

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAveir VR Leadless Pacemaker System

This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.